Published in Exp Ther Med on February 16, 2016
Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11
Aneuploidy and cancer. Nature (2004) 5.61
7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol (2010) 4.52
Multimodality therapy for esophageal cancer. Oncology (Williston Park) (2010) 2.13
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol (2010) 1.31
Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol (2007) 1.30
Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res (2003) 1.20
Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer (2006) 1.15
A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol (2008) 1.12
Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer (2004) 0.99
Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update. Am J Surg Pathol (2014) 0.96
Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol (2005) 0.96
Barrett esophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol (2009) 0.95
HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer (2014) 0.93
Quantitative detection of lung cancer cells by fluorescence in situ hybridization: comparison with conventional cytology. Chest (2005) 0.91
Histology of metaplasia and dysplasia in Barrett's esophagus. Surg Oncol Clin N Am (2009) 0.85
Genetic diagnosis of patients with esophageal cancer using FISH. Oncol Lett (2010) 0.82
Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients. Cell Cycle (2014) 0.80
Molecular pathological diagnosis for early esophageal cancer in Kazakh patients. Oncol Lett (2011) 0.80
TP53 gene deletion in esophageal cancer tissues of patients and its clinical significance. Mol Med Rep (2012) 0.80
Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study. J Clin Pathol (2013) 0.79
Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas. Exp Mol Pathol (2014) 0.78
Molecular pathological diagnosis for early esophageal cancer in Kazakh patients. Oncol Lett (2011) 0.80
Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China. Mol Clin Oncol (2015) 0.78
Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma. Oncol Lett (2015) 0.75